• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Survey: clinical trial costs rapidly increasing

Survey: clinical trial costs rapidly increasing

July 27, 2011
CenterWatch Staff

Increasing competition for trial sites and CROs that can yield reliable, high-quality data is raising the costs of clinical trials, according to a recent survey from Cutting Edge Information.

Pharmalot reported that 32% of those surveyed pointed to higher costs for enrolling patients and 25% cited vendor fees. Expenses for recruiting trial sites was named by 14%, followed by 12% who fingered technology costs, according to the survey of 21 drug makers, 12 biotechs, nine device makers and 23 CROs.

Meanwhile, staffing for drug development is rising. For instance, phase IV staffing increased by 85% from 2008 to 2011, while phase IIIa doubled. Phase IIIb staffing rose 57%, phase II staffing jumped 106% and phase I staffing spiked 108%. One big reason – more clinical research associates. In 2008, the average phase II trial employed 3.6 CRAs, but that rose to 9 in 2011. The average ratio of CRAs per site was 10 in phase IIIb and 6.3 in phase IIIa.

As for the average per-patient trial costs across all therapeutic areas, in phase I, costs rose from $15,023 in 2008 to $21,883 in 2011. Phase II cost rose from $21,009 to $36,070. In phase IIIa, the cost increased from $25,280 to $47,523 and for phase IIIb, cost jumped from $25,707 to $47,095. Phase IV expenses rose from $13,011 to $17.042.

“Everybody is working hard to control those costs. The biggest thing on the horizon is trying to get a handle on earlier go-no-go decisions,” Cutting Edge COO Adam Bianchi told Pharmalot. “The competition for quality sites is creating a lot of headaches. You have a greater number of sites worldwide than ever before, but not all are yielding quality data that companies want.”

More clinical trial work is being outsourced. For phase I trials, 58% is now outsourced, compared with 35% in 2008. In phase II, the figure is 63%, up from 36%. In phase IIIb, 54% is outsourced versus 46%, and in phase IV, 51% is now outsourced, compared with 43% three years ago.

The recent average cost per patient for a cardiovascular trial in phase IIIa was $21,750, and $6,830 in phase IIIb. The cost for phase II was $33,700. In oncology, the average per patient trial cost for phase IIIa was $57,207 and $65,900 for phase IIIb. For phase II, the average cost was $73,303. For drug to treat central nervous system disorders, phase IIIb costs were $41,824 and phase IIIa costs were $33,768, on average per patient. Phase II was $28,197. And for diabetes, phase IIIb costs were $10,700, phase IIIa costs were $12,667 and phase II costs were $8,854.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing